On Friday, 10x Genomics Inc (NASDAQ: TXG) opened higher 4.03% from the last session, before settling in for the closing price of $7.70. Price fluctuations for TXG have ranged from $6.78 to $36.46 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 21.90% over the past five years. Company’s average yearly earnings per share was noted -0.01% at the time writing. With a float of $100.79 million, this company’s outstanding shares have now reached $108.24 million.
Let’s look at the performance matrix of the company that is accounted for 1306 employees. In terms of profitability, gross margin is 68.73%, operating margin of -31.51%, and the pretax margin is -29.09%.
10x Genomics Inc (TXG) Insider Updates
A key investor’s attitude towards the stock of the Health Information Services industry is another important factor to consider. The insider ownership of 10x Genomics Inc is 17.59%, while institutional ownership is 83.15%. The most recent insider transaction that took place on Feb 28 ’25, was worth 84,393. In this transaction Chief Executive Officer of this company sold 7,942 shares at a rate of $10.63, taking the stock ownership to the 871,540 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director, CEO proposed sale 7,942 for $10.57, making the entire transaction worth $83,947.
10x Genomics Inc (TXG) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.93% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Check out the current performance indicators for 10x Genomics Inc (TXG). In the past quarter, the stock posted a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
10x Genomics Inc (NASDAQ: TXG) saw its 5-day average volume 4.11 million, a positive change from its year-to-date volume of 2.95 million. As of the previous 9 days, the stock’s Stochastic %D was 52.67%. Additionally, its Average True Range was 0.85.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 11.75%, which indicates a significant decrease from 33.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.08% in the past 14 days, which was higher than the 77.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.75, while its 200-day Moving Average is $16.10. Nevertheless, the first resistance level for the watch stands at $8.24 in the near term. At $8.47, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.87. If the price goes on to break the first support level at $7.60, it is likely to go to the next support level at $7.20. Assuming the price breaks the second support level, the third support level stands at $6.97.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are currently 122,302K shares outstanding in the company with a market cap of 979.62 million. Presently, the company’s annual sales total 610,790 K according to its annual income of -182,630 K. Last quarter, the company’s sales amounted to 165,020 K and its income totaled -49,030 K.
